Rapid automation of a cell-based assay using a modular approach: case study of a flow-based Varicella Zoster Virus infectivity assay
- PMID: 20117140
- DOI: 10.1016/j.jviromet.2010.01.016
Rapid automation of a cell-based assay using a modular approach: case study of a flow-based Varicella Zoster Virus infectivity assay
Abstract
Vaccine manufacturing requires constant analytical monitoring to ensure reliable quality and a consistent safety profile of the final product. Concentration and bioactivity of active components of the vaccine are key attributes routinely evaluated throughout the manufacturing cycle and for product release and dosage. In the case of live attenuated virus vaccines, bioactivity is traditionally measured in vitro by infection of susceptible cells with the vaccine followed by quantification of virus replication, cytopathology or expression of viral markers. These assays are typically multi-day procedures that require trained technicians and constant attention. Considering the need for high volumes of testing, automation and streamlining of these assays is highly desirable. In this study, the automation and streamlining of a complex infectivity assay for Varicella Zoster Virus (VZV) containing test articles is presented. The automation procedure was completed using existing liquid handling infrastructure in a modular fashion, limiting custom-designed elements to a minimum to facilitate transposition. In addition, cellular senescence data provided an optimal population doubling range for long term, reliable assay operation at high throughput. The results presented in this study demonstrate a successful automation paradigm resulting in an eightfold increase in throughput while maintaining assay performance characteristics comparable to the original assay.
Copyright 2010 Elsevier B.V. All rights reserved.
Similar articles
-
T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine.J Immunol. 1989 Jan 15;142(2):636-41. J Immunol. 1989. PMID: 2536059
-
Transmission of varicella to a gravida via close contacts immunized with varicella-zoster vaccine. A case report.J Reprod Med. 1999 Oct;44(10):905-7. J Reprod Med. 1999. PMID: 10554758
-
Immunogenicity of a two-dose regime of varicella vaccine in children with cancers.Eur J Haematol. 2004 May;72(5):353-7. doi: 10.1111/j.1600-0609.2004.00216.x. Eur J Haematol. 2004. PMID: 15059071
-
Investigations of the pathogenesis of Varicella zoster virus infection in the SCIDhu mouse model.Herpes. 2006 Nov;13(3):75-80. Herpes. 2006. PMID: 17147912 Review.
-
The safety profile of varicella vaccine: a 10-year review.J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9. doi: 10.1086/522125. J Infect Dis. 2008. PMID: 18419392 Review.
Cited by
-
A High-Throughput and Robust Relative Potency Assay Measuring Human Cytomegalovirus Infection in Epithelial Cells for Vaccine Development.Vaccines (Basel). 2025 Jun 10;13(6):626. doi: 10.3390/vaccines13060626. Vaccines (Basel). 2025. PMID: 40573957 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources